Response Assessment: Monitoring Parameters and Molecular Testing Integration
June 19th 2025Panelists discuss how to monitor patients on JAK inhibitors, including blood count checks every 1 to 2 weeks initially, baseline spleen imaging with follow-up at 3 to 6 months, and symptom burden assessment.
Watch
Real-World Experience with Ruxolitinib in SR cGvHD
June 19th 2025A panelist discusses how real-world experience with ruxolitinib and belumosidil shows similar response rates to clinical trials (45% and 65% respectively), emphasizes the importance of antimicrobial prophylaxis and supportive care, and describes gradual steroid tapering strategies once patients achieve responses.
Watch
An expert emphasizes that genomic profiling—including both germline and somatic testing—is now essential in metastatic prostate cancer management because it identifies key mutations such as homologous recombination repair (HRR) gene alterations that guide targeted therapies such as PARP inhibitors, informs the use of immune checkpoint inhibitors in select cases, and helps predict disease aggressiveness to tailor monitoring and treatment strategies.
Watch
Recent Clinical Trial Data in mCRPC
June 16th 2025An expert discusses recent trial data showing that combining radium-223 with enzalutamide modestly improves outcomes in metastatic castration-resistant prostate cancer (mCRPC) with bone metastases—highlighting the necessity of bone-modifying agents to reduce fracture risk—while results from the TRITON3 trial underscore the greater efficacy of PARP inhibitors such as rucaparib when used early and in combination for BRCA-mutated patients.
Watch